Clementia Pharma May Be A Fit For Investors Looking For Undervalued Biotech Names
August 28, 2017 at 15:06 PM EDT
Wedbush initiated coverage of Clementia Pharmaceuticals Inc (NASDAQ: CMTA) at Outperform and a $26 price target. The firm believes ...